Q2 2026 revenues declined 2% year-over-year to $783.3 million, but net income rose 8% to $333.0 million, driven by product mix and lower tax rate. Regulatory filings and organ manufacturing initiatives signal future growth, while share repurchases boosted shareholder returns.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.